ELEKTA AND MARY BIRD PERKINS CANCER CENTER SIGN STRATEGIC MULTI-CENTER RADIATION THERAPY SYSTEMS AGREEMENT

ELEKTA AND MARY BIRD PERKINS CANCER CENTER SIGN STRATEGIC MULTI-CENTER RADIATION
THERAPY SYSTEMS AGREEMENT

Press Release 
Stockholm, Sweden, June 5, 2008

Elekta, a world class leader in advanced radiation therapy and radiosurgery, has
been selected to supply multiple Elekta Synergy® digital linear accelerator
systems to Mary Bird Perkins Cancer Center over the next few years. 

The new Elekta Synergy systems will provide expanded capacity for advanced Image
Guided Radiation Therapy (IGRT) which Mary Bird Perkins (MBP) began providing to
patients four years ago. The new systems will provide for MBP's current
locations as well as the organization's long-term regional growth into new
markets. MBP has locations in Baton Rouge, Hammond and Covington and is building
a fourth location in Gonzales, LA. 

Each of the estimated nine new treatment systems will include 3D X-ray Volume
Imaging (XVI) and some will include Elekta VMAT (Volumetric intensity Modulated
Arc Therapy), enhancing MBP's Intensity Modulated Radiation Therapy (IMRT) and
IGRT arsenal.  

“We feel that Elekta is ‘first class in its field' and provides dynamic,
practical and reliable treatment options,” said Todd D. Stevens, President and
CEO, MBP. “Every cancer case is unique and personal, and Mary Bird Perkins makes
sure that it has the best radiation therapy options available to our treatment
team so every cancer patient has individualized, optimal treatment.”

The Center will be treating all types of cancer with the Elekta Synergy systems,
from simple to the most complex cases. Elekta Synergy is a fully digital linear
accelerator with an integrated 3D imaging system that simultaneously acquires
and reconstructs image data on the target and surrounding critical structures as
a whole volume in a single gantry sweep. Because imaging occurs at the time of
treatment, uncertainties due to organ motion or deformation and slight
differences in patient set-up can be eliminated.

In its search for the best solution for patient care, Mary Bird Perkins
diligently analyzed all proposals and mobilized a team of expert physicians,
medical physicists, dosimetrists and radiation therapists to thoroughly research
and review all options. “Elekta won a very competitive award, and we chose them
because they offered a better solution for our patients,” said Dr. Kenneth
Hogstrom, chief of physics, MBP.  

Joseph K. Jachinowski, President and CEO of Elekta North America stated: “We are
extremely pleased to be able to supply our treatment delivery devices to Mary
Bird Perkins. They have been a long time user of our Electronic Medical Record
(EMR) system and the combination of adding Elekta Synergy treatment systems with
the EMR will further enhance the integration of the delivery of cancer care
benefiting patients across Mary Bird Perkins' network of facilities.”

VMAT with Elekta Synergy®
MBP makes it a priority to always be a pioneering user of new technologies that
will improve patient outcomes. Elekta Synergy will enable the institution to
implement Elekta VMAT* (Volumetric intensity Modulated Arc Therapy). This major
advancement in radiation therapy surpasses traditional IMRT techniques by
dramatically decreasing treatment times and providing highly conformal radiation
dose distributions. 

“In many cases, we feel Elekta VMAT will allow us to produce plans that are
superior to those using conventional gantry-static IMRT deliveries,” says Dr.
John Gibbons, chief of clinical physics, MBP. “We look forward to helping Elekta
deploy the application of VMAT technology for the benefit of cancer patients in
Louisiana.”

Elekta's VMAT solution will vary the monitor units (MU) per degree and beam
intensities “on the fly” by simultaneously manipulating gantry position and
speed, MLC leaves, dose rate, collimator angle and back-up diaphragms, all while
the treatment beam is on. Additionally, where IMRT plans consist of several
fields, or control points, the VMAT technique effectively has an unlimited
number of fields. 

Elekta believes VMAT's shorter treatment times translate into increased patient
comfort by reducing time spent during treatment.   

The Center also is using all available aspects of the MOSAIQ® image-enabled
oncology electronic medical record (EMR) system. MOSAIQ supports and streamlines
the entire cancer care workflow process, from initial diagnosis and staging
through scheduling, planning, treatment, billing and subsequent follow-up.

*Elekta VMAT is pending FDA 510(k) premarket clearance and is not yet available
for commercial delivery in the US.

******






For further information, please contact:

Peter Ejemyr, Group VP Corporate Communications.
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 5,000 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With around 2,500 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.